{"id":399379,"date":"2020-12-14T16:08:38","date_gmt":"2020-12-14T21:08:38","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=399379"},"modified":"2020-12-14T16:08:38","modified_gmt":"2020-12-14T21:08:38","slug":"shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\/","title":{"rendered":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Alexion Pharmaceuticals, Inc."},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n NEW YORK<\/span>, Dec. 14, 2020<\/span> \/PRNewswire\/ — WeissLaw LLP<\/a>\u00a0is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alexion Pharmaceuticals, Inc. (“Alexion” or the “Company”) (NASDAQ: ALXN) in connection with the proposed acquisition of the Company by\u00a0AstraZeneca PLC (“AstraZeneca”), a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines. \u00a0Under the terms of the acquisition agreement, the Company’s shareholders will receive $60.00<\/span> per share in cash and 2.1243 AstraZeneca American Depositary Shares (“ADSs”) (each ADS representing one-half of one ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (“ADRs”)) for each share of Alexion common stock that they hold.\u00a0 Based on AstraZeneca’s reference average ADR price of $54.14<\/span>, this implies total consideration to Alexion shareholders of $175<\/span> per share.<\/p>\n

\n

\n
\n \"WeissLaw
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n
\n If you own Alexion shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:<\/u>
\n <\/b>\n <\/p>\n

\n
\n http:\/\/www.weisslawllp.com\/ALXN\/<\/a>
\n <\/b>\n <\/p>\n

\n
\n Or please contact:
<\/u>
\n <\/b>
\n
\n Joshua Rubin, Esq.<\/span>
\n
\n <\/b>WeissLaw LLP
1500 Broadway, 16th<\/sup> Floor
New York<\/span>, NY\u00a0 10036
(212)\u00a0682-3025
<\/b>(888) 593-4771
stockinfo@weisslawllp.com<\/a><\/b><\/p>\n

WeissLaw is investigating whether (i) Alexion’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the merger consideration adequately compensates Alexion’s shareholders; and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed. \u00a0Notably, at least one analyst has set a price target for the Company of\u00a0$200.00, and the merger consideration is 14% below the Company’s all time high stock price.<\/p>\n

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.\u00a0 We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.\u00a0 If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com<\/a><\/b><\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc-301192370.html<\/a><\/p>\n

SOURCE WeissLaw LLP<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK, Dec. 14, 2020 \/PRNewswire\/ — WeissLaw LLP\u00a0is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alexion Pharmaceuticals, Inc. (“Alexion” or the “Company”) (NASDAQ: ALXN) in connection with the proposed acquisition of the Company by\u00a0AstraZeneca PLC (“AstraZeneca”), a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines. \u00a0Under the terms of the acquisition agreement, the Company’s shareholders will receive $60.00 per share in cash and 2.1243 AstraZeneca American Depositary Shares (“ADSs”) (each ADS representing one-half of one ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (“ADRs”)) for each share of Alexion common stock that they hold.\u00a0 Based on AstraZeneca’s reference … <\/p>\n

Continue reading “SHAREHOLDER ALERT: WeissLaw LLP Investigates Alexion Pharmaceuticals, Inc.”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-399379","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSHAREHOLDER ALERT: WeissLaw LLP Investigates Alexion Pharmaceuticals, Inc. - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SHAREHOLDER ALERT: WeissLaw LLP Investigates Alexion Pharmaceuticals, Inc. - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, Dec. 14, 2020 \/PRNewswire\/ — WeissLaw LLP\u00a0is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alexion Pharmaceuticals, Inc. (“Alexion” or the “Company”) (NASDAQ: ALXN) in connection with the proposed acquisition of the Company by\u00a0AstraZeneca PLC (“AstraZeneca”), a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines. \u00a0Under the terms of the acquisition agreement, the Company’s shareholders will receive $60.00 per share in cash and 2.1243 AstraZeneca American Depositary Shares (“ADSs”) (each ADS representing one-half of one ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (“ADRs”)) for each share of Alexion common stock that they hold.\u00a0 Based on AstraZeneca’s reference … Continue reading "SHAREHOLDER ALERT: WeissLaw LLP Investigates Alexion Pharmaceuticals, Inc."\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-14T21:08:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SHAREHOLDER ALERT: WeissLaw LLP Investigates Alexion Pharmaceuticals, Inc.\",\"datePublished\":\"2020-12-14T21:08:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\\\/\"},\"wordCount\":370,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/743985\\\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\\\/\",\"name\":\"SHAREHOLDER ALERT: WeissLaw LLP Investigates Alexion Pharmaceuticals, Inc. - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/743985\\\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\",\"datePublished\":\"2020-12-14T21:08:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/743985\\\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/743985\\\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SHAREHOLDER ALERT: WeissLaw LLP Investigates Alexion Pharmaceuticals, Inc.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Alexion Pharmaceuticals, Inc. - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\/","og_locale":"en_US","og_type":"article","og_title":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Alexion Pharmaceuticals, Inc. - Market Newsdesk","og_description":"PR Newswire NEW YORK, Dec. 14, 2020 \/PRNewswire\/ — WeissLaw LLP\u00a0is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alexion Pharmaceuticals, Inc. (“Alexion” or the “Company”) (NASDAQ: ALXN) in connection with the proposed acquisition of the Company by\u00a0AstraZeneca PLC (“AstraZeneca”), a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines. \u00a0Under the terms of the acquisition agreement, the Company’s shareholders will receive $60.00 per share in cash and 2.1243 AstraZeneca American Depositary Shares (“ADSs”) (each ADS representing one-half of one ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (“ADRs”)) for each share of Alexion common stock that they hold.\u00a0 Based on AstraZeneca’s reference … Continue reading \"SHAREHOLDER ALERT: WeissLaw LLP Investigates Alexion Pharmaceuticals, Inc.\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-14T21:08:38+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Alexion Pharmaceuticals, Inc.","datePublished":"2020-12-14T21:08:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\/"},"wordCount":370,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\/","name":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Alexion Pharmaceuticals, Inc. - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg","datePublished":"2020-12-14T21:08:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-alexion-pharmaceuticals-inc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Alexion Pharmaceuticals, Inc."}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/399379","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=399379"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/399379\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=399379"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=399379"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=399379"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}